Tissue reactive compounds and compositions and uses thereof
申请人:Angiotech International AG
公开号:US20040219214A1
公开(公告)日:2004-11-04
A composition comprising a synthetic polymer, optionally in the presence of a drug, where the polymer comprises multiple activated groups. The multiple activated groups are reactive with functionality present on animal tissue, so that upon administration of the polymer to the tissue, the polymer binds to the tissue. Alternatively, the multiple activated groups are reactive with functionality present on a non-living surface, where the polymer binds to this surface to, e.g., increase the lubricity of the surface. When drug is present in the composition, the drug is then delivered to the site of polymer attachment.
Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.
Compounds having one or more aminosulfonyloxy radicals useful as pharmaceuticals
申请人:A.H. ROBINS COMPANY, INCORPORATED
公开号:EP0403185A2
公开(公告)日:1990-12-19
The invention concerns known and novel compounds which fall under the general formula:
wherein A encompasses a wide range of values including but not limited to aryl, loweralkyl, cycloalkyl, and carbohydrates including sucrose and fructose; p is equal to the number of hydroxy groups on A and may be zero; z is the number of -OS(O)2NR1R2 groups and is always at least one; R1 and R2 are selected from hydrogen, loweralkyl, carboxy and the like; which compounds are useful for treating chronic arthritis and osteoporosis. A novel process for preparing the compounds is provided wherein an appropriate sulfamic acid aryl ester is reacted with a a hydroxy substituted A radical which may or may not contain thereon protected carboxyl, amino or hydroxy substituents, in an aprotic solvent containing a tertiary amine base. Pharmaceutical compositions for the treatment of chronic arthritis and osteoporosis are also provided.
本发明涉及属于通式的已知和新型化合物:
其中,A 的数值范围很广,包括但不限于芳基、低级烷基、环烷基以及包括蔗糖和果糖在内的碳水化合物;p 等于 A 上羟基的数目,可以是零;z 是 -OS(O)2NR1R2 基团的数目,总是至少一个;R1 和 R2 选自氢、低级烷基、羧基等;这些化合物可用于治疗慢性关节炎和骨质疏松症。本发明提供了一种制备这些化合物的新工艺,即在含有叔胺基的钝溶剂中,将适当的氨基磺酸芳基酯与羟基取代的 A 基反应,A 基上可以含有或不含有受保护的羧基、氨基或羟基取代基。此外,还提供了用于治疗慢性关节炎和骨质疏松症的药物组合物。
Drug delivery from rapid gelling polymer composition
申请人:ANGIOTECH INTERNATIONAL AG
公开号:EP2181704A2
公开(公告)日:2010-05-05
Compositions are disclosed that afford drug delivery from two-part polymer compositions that rapidly form covalent linkages when mixed together. Such compositions are particularly well suited for use in a variety of tissue related applications when rapid adhesion to the tissue and gel formation is desired along with drug delivery. For example, the compositions are useful as tissue sealants, in promoting hemostasis, in effecting tissue adhesion, in providing tissue augmentation, and in prevention of surgical adhesions.
Anastomotic connector devices are provided which release a therapeutic agent. The therapeutic agent may be an anti-scarring agent that inhibits stenosis caused by the presence of the anastomotic connector device.